Drug Trial Radar · NCT02873936
Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment
Last checked: Nov 20, 2026Latest source record: May 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
449
Actual
Start
Jul 27, 2016
Primary completion
Mar 20, 2018
Study completion Jun 26, 2018
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- Collaborators
- Lakefront Biotherapeutics NV
- First posted
- Aug 22, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.
Conditions
- Rheumatoid Arthritis
Interventions
FilgotinibDrug
Tablet(s) administered orally once daily
Placebo to match filgotinibDrug
Tablet(s) administered orally once daily
csDMARDsDrug
csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX is not allowed)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12Time frame: Week 12
Locations
104 sites in 15 countries. Site status is shown where the registry gives one.
Site not named
Huntsville, Alabama
Site not named
Gilbert, Arizona
Site not named
Covina, California
Site not named
Hemet, California
Site not named
La Jolla, California
Site not named
Palm Desert, California
Site not named
Palo Alto, California
Site not named
Riverside, California
Site not named
Upland, California
Site not named
Victorville, California
Site not named
Whittier, California
Site not named
Aventura, Florida
Site not named
DeBary, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
Plantation, Florida
Site not named
Port Richey, Florida
Site not named
Decatur, Georgia
Site not named
Kansas City, Kansas
Site not named
Wichita, Kansas
Site not named
Elizabethtown, Kentucky
Site not named
Lexington, Kentucky
Site not named
Cumberland, Maryland
Site not named
Frederick, Maryland
Site not named
Worcester, Massachusetts
Site not named
Detroit, Michigan
Site not named
Saint Clair Shores, Michigan
Site not named
Hattiesburg, Mississippi
Site not named
Tupelo, Mississippi
Site not named
St Louis, Missouri
Site not named
Lincoln, Nebraska
Site not named
Lebanon, New Hampshire
Site not named
Freehold, New Jersey
Site not named
Toms River, New Jersey
Site not named
Brooklyn, New York
Site not named
Charlotte, North Carolina
Site not named
Greenville, North Carolina
Site not named
Salisbury, North Carolina
Site not named
Middleburg Heights, Ohio
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.